Practical PMS guidance for FDA and Health Canada first — with selected global reference content where useful. Written from the RA/QA perspective.
A side-by-side comparison of FDA and Health Canada post-market surveillance requirements for medical device manufacturers selling in both markets — covering reporting obligations, timelines, audit expectations, and harmonization under MDSAP.
Everything RA/QA professionals need to know about Health Canada's post-market surveillance requirements — mandatory problem reporting under CMDR, recall procedures, MDALL licence obligations, and MDSAP audit expectations.
A comprehensive reference for RA/QA professionals on FDA post-market surveillance requirements — covering MDR reporting (21 CFR 803), complaint handling, CAPA, trend analysis, and QMSR 2026 changes.
This week’s FDA external signals reinforce a familiar RA/QA reality: your audit risk isn’t “missing a recall headline”—it’s failing to prove you reviewed it, assessed relevance, and recorded a decision. A high-quality external PMS system must produce: (1) a clear signal list, (2) relevance triage + rationale, (3) timestamps (Published/Captured/Reviewed), and (4) an exportable evidence pack.
This week saw 12 new FDA device recalls including 3 Class I events, plus Health Canada updated 47 medical device listings. Here is what your RA/QA team needs to know.
External PMS means monitoring publicly available regulatory signals for events related to your device. Here is what the standards require and how to build an audit-ready evidence system.
By TrueMedDevice Team · Mar 25, 2026 · 5 min read | Today's FDA enforcement actions expose critical gaps in labeling adequacy, software validation, and supplier quality management that could trigger regulatory scrutiny across device categories.
Enter your device and see what needs review